Durham, N.C.-based Med-El North America received a thumbs up from the FDA for use of its cochlear implant systems in people with single-sided deafness (SSD) and asymmetrical hearing loss (AHL). The July 19 approval marks the first time that Americans with these two indications are eligible for the surgically implanted electronic device, which until now has been limited to people with profound or severe bilateral hearing loss.

Deep learning algorithms developed at the Memorial Sloan Kettering Cancer Center (MSK) were able to distinguish prostate, skin and breast cancer with nearly perfect accuracy in a recent clinical trial. The technology has already been licensed exclusively by New York-based startup Paige.AI, which snapped up a $25 million series A early last year to continue to advance it.